sameAs
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes AssociationMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesGlycemic Targets in Diabetes Care: Emerging Clarity after AccordManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesEffect of valsartan on the incidence of diabetes and cardiovascular eventsStrategies for multivessel revascularization in patients with diabetesExenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyAssociations between arsenic species in exfoliated urothelial cells and prevalence of diabetes among residents of Chihuahua, MexicoGenetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial.Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals.Maria Gordon Buse, MD: A Family Affair Through Six Decades of Diabetes Discovery.Novel measures of inflammation and insulin resistance are related to obesity and fitness in a diverse sample of 11-14 year olds: The HEALTHY Study.LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trDevelopment and validation of the Diabetes Numeracy Test (DNT)The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD studyIncretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trialThree approaches to glucose monitoring in non-insulin treated diabetes: a pragmatic randomized clinical trial protocolEpidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.Management of glycemia in type 2 diabetes.Long-term effects of intensive glucose lowering on cardiovascular outcomes.Effects of combination lipid therapy in type 2 diabetes mellitus.Association of cardiac and vascular changes with ambient PM2.5 in diabetic individualsThe metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.Effects of intensive blood-pressure control in type 2 diabetes mellitus.Cardiometabolic risk assessments by body mass index z-score or waist-to-height ratio in a multiethnic sample of sixth-graders.Recommendations for management of diabetes during Ramadan: update 2010.Small intestine hexose transport in experimental diabetes. Increased transporter mRNA and protein expression in enterocytes.Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker.We can change the natural history of type 2 diabetes.Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority triaElectronic medical record cancer incidence over six years comparing new users of glargine with new users of NPH insulinLack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery
P50
Q22241288-3EE53A31-924B-42D0-BA7E-9931B3A1D78BQ22241916-CAEEA134-BD0C-48F5-8623-7945B5F7E532Q24642503-D2A3CD83-37AF-4F0A-8669-C60E97E871F6Q26795380-AA6604D2-D0DD-453D-94CC-FC0380A29B86Q28254549-9F350D5E-0834-46D8-8C67-5D15FF1D9F90Q28275975-612096EE-CFF1-4B73-B9DA-117BD7BAC1E0Q28278561-0795E012-9351-4221-BEF8-213B68448C7DQ28293505-314976BD-292D-4FA7-99F9-26BC65FD4B50Q28395150-467AFDB8-4425-4CA0-BF05-09BE9B2551AEQ30276113-B64EEC13-00CA-47C5-A987-94DF6A0CB3AAQ30392979-75FA3F92-9683-4D7B-ADBE-B5DF1E0BB905Q30419512-2593C67A-1D71-47D1-868B-EA7BF54DFE49Q30492179-8F953B11-FAAC-49A7-8BA4-749250B5051BQ30571123-A92EB619-E00A-4882-B1ED-BF88A5F222A7Q30781511-14272623-2EBD-4EE0-8360-E797CE2E6284Q30856973-0DCFCEF2-B989-4F4A-9A65-E430675141D0Q30888375-E7A8998E-8FD6-45ED-883F-1FAB53A61C3EQ33279692-FDC0FA8F-333B-4DE7-BCD7-1674825477DCQ33331477-87560D2B-ACF1-46B0-BE15-5A8CA6B4EC76Q33579765-AEDF4014-2049-47EA-9989-D97CF33B2BADQ33602360-AD0B3D51-227A-42C7-92DA-1F230B9ED212Q33646630-18BC3AE5-B3F1-448E-9E9B-30FBEAAC5533Q33730372-B397E04E-5139-4A54-A52F-2BD62A036683Q33804791-44A8B5D2-4215-4D2A-B99B-DE69D0B45883Q33842446-F5F75489-6A05-4C0E-83B1-A042417A85E2Q33851861-5EB70B0D-D268-4DC0-BF14-CC484DEF82D3Q33889260-5C74369B-389C-451C-808B-3669CA322148Q33961204-F002907A-4A4D-47FC-8740-A95504A5ECDCQ33989576-06BE9461-B17E-4F7F-B5AE-583E635BBE61Q34008161-A9F3638B-B1D3-4676-8304-3B3060852808Q34009642-08399F9E-111A-48F8-95DC-9D9463D9F49DQ34016169-7C3A196A-0F8F-454F-96F4-69EA1466D04FQ34124810-7D296A51-ACA5-4B29-9C23-645A619AC105Q34209188-BC2777DB-5769-4715-9C16-C79BAEE3B775Q34219402-048A9705-0EEA-4481-BEF7-04CAD455137CQ34269828-976D35CB-7D8A-495E-80FF-C5D98347A333Q34373861-78840AF3-AD9B-4535-B626-6E8B1A70A77FQ34442253-92130451-5D2E-4D62-AEB0-5EA4C1B41260Q34457919-70DC74DF-2911-4A07-B734-FE6622F65DABQ34481917-6911D815-CC0B-4B1E-9602-FE99E0F788AF
P50
description
American academic
@en
Amerikaans onderzoeker
@nl
académico estadounidense
@es
name
John B Buse
@sl
John Buse
@de
John Buse
@en
John Buse
@es
John Buse
@fr
John Buse
@nl
type
label
John B Buse
@sl
John Buse
@de
John Buse
@en
John Buse
@es
John Buse
@fr
John Buse
@nl
altLabel
John B Buse
@en
John B Buse
@fr
John B Buse
@nl
John B. Buse
@en
John B. Buse
@fr
John Bernard Buse
@en
John Bernard Buse
@fr
prefLabel
John B Buse
@sl
John Buse
@de
John Buse
@en
John Buse
@es
John Buse
@fr
John Buse
@nl
P214
P106
P1280
P21
P214
P31
P496
0000-0002-9723-3876
P735
P7859
lccn-nr2002019958